ALFA Finder| EBITDA Margin guidance | 22.0% → 25.0% Raised by 3.0 percentage points |
|---|---|
| Management target | Revenue FY27 |
| Revenue growth | 5% annual revenue growth to 288Cr in FY26. |
|---|---|
| Margins | EBITDA margin stable at 22%; aiming for 25% post-expansion. |
| Demand visibility | Strong IV fluid demand, especially for advanced two-port systems. |
| Management confidence | High, focused on specialized high-margin product mix and cost efficiency. |
Growth
Revenue grew 5% YoY to 288Cr, while PAT surged 42% supported by better operating leverage and debt refinancing.
Outlook
EBITDA margins guided to expand from 22% to 25% following Steriport expansion and solar project commissioning.
Risks
Rising polymer costs (60-70% spike) and temporary inventory pile-ups during capacity ramp-up represent short-term headwinds.
Last quarter's promises, checked
Delivered
- Debt-to-equity ratio 3x → delivered ~1x (= BEAT)
- SteriPort revenue share → delivered 42% (= BEAT)
- EBITDA margin → delivered 22% (= BEAT)
Partly delivered
- Solar project commissioning → delivered 5-6 days away (= PARTIAL)
- SteriPort capacity expansion → delivered June 20th target (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: AMANTA. Summary written with AI assistance from the document.
Amanta Healthcare Ltd: key numbers
- Share price
- ₹197.15
- Market cap
- ₹765.5 Cr
- Revenue (annual)
- ₹287.7 Cr
- Net profit (annual)
- ₹14.88 Cr
- P/E (TTM)
- 41.8×Sector 43.8×
- Promoter holding
- 63.80%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amanta Healthcare Ltd
All →Amanta Healthcare Promoter Buying (Off-Market): ₹5.4 Cr
Promoter Jitendrakumar Patel bought 3,00,150 Amanta Healthcare shares off-market for about Rs 5.40 Crore. Promoter holding rises from 9.02% to 9.79%.
- Value
- ₹5.40 Cr
- Promoter stake change
- +0.77%
Amanta Healthcare Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹83.1 Cr (+17%), PAT ₹4.86 Cr (+26%), EBITDA margin 21.6%. The FY27 ₹420–430 Cr target needs a steep H2 ramp the Q2 run-rate doesn't support.
- Call
- Guides 20% growth
Amanta Healthcare Investor Presentation: Key Takeaways
Q2FY27 revenue ₹83.1 Cr (+17.3% YoY), EBITDA ₹17.95 Cr (21.6% margin), PAT ₹4.86 Cr. H1 revenue ₹151.9 Cr, PAT ₹8.2 Cr. SteriPort Line 3 commissioned September 2026.
- Call
- Guides 20% growth
Amanta Healthcare Results Update
Amanta Healthcare reported Q2FY27 revenue of ₹83.13 crore and PAT of ₹4.86 crore, both up sharply YoY. SteriPort Line 3 was commissioned, raising bottle capacity to 11.6 crore.
- SteriPort bottle capacity
- 11.6 crore bottles
Amanta Healthcare Q2 FY27 Results: Net Profit ₹4.9 Cr, Up 308.3% YoY
Amanta Healthcare Ltd reported revenue from operations of ₹83.1 Cr (+17.2% YoY) and net profit of ₹4.9 Cr (+308.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹4.9 Cr · +308.3% YoY
Amanta Healthcare Other Announcement
Amanta Healthcare's quarterly shareholding pattern as at 30 Sep 2026 shows promoter and promoter group holding at 31.33%. The filing notes a gift-based promoter group addition, but is a routine periodic disclosure.